Tango Therapeutics, Inc. cash flow to debt ratio of -413.72% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Tango Therapeutics, Inc.'s free cash flow has decreased 5.81% from $-132.25M last year to $-139.93M, signaling decreasing performance

Tango Therapeutics, Inc.'s debt to equity ratio is 0.08, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Tango Therapeutics, Inc.'s debt has decreased relative to shareholder equity from 0.18 last year to 0.08 today, signaling strengthened financials

Tango Therapeutics, Inc. has negative EBITDA, making leverage ratio unreliable

Tango Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Tango Therapeutics, Inc.'s profit margin has increased (-39.25%) in the last year from -309.73% to -188.15%, signaling increasing performance

Tango Therapeutics, Inc.'s short-term assets of $353.76M exceed its short-term liabilities of $21.68M

Tango Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Tango Therapeutics, Inc.'s return on equity of -41.54%, is lower than 15.00%, indicating bad performance

Tango Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Tango Therapeutics, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Tango Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Tango Therapeutics, Inc. has negative free cash flow, indicating cash burn

Tango Therapeutics, Inc.'s yearly earnings has increased -22.03% since last year from $-130.30M to $-101.59M, signaling increasing performance

Tango Therapeutics, Inc.'s yearly revenue has increased 48.29% since last year from $42.07M to $62.38M, signaling increasing performance

ROIC -27.69% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Tango Therapeutics, Inc.'s 3-year revenue CAGR of 35.89% is positive, indicating growing revenue over the past 3 years

Tango Therapeutics, Inc. had revenue growth in 4.00 out of 5 years, indicating consistent revenue performance

Tango Therapeutics, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Tango Therapeutics, Inc. has insufficient data to evaluate this check.

Tango Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Tango Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Tango Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Tango Therapeutics, Inc. is overvalued relative to its fair value price of -32.49 based on Earnings Fair Value model

Tango Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Tango Therapeutics, Inc. has a price-to-book ratio of 10.87x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Tango Therapeutics, Inc. has a price-to-sales ratio of 74.70x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue